Acute heart failure: inotropic agents and their clinical uses

Bibliography

• KATZ AM: Heart Failure – Pathophysiology, Molecular Biology, and Clinical Management, 1st edn. Lippincott Williams & Wilkins, Philadelphia, PA, USA (2000).
   Google Scholar
• CHIN BS, LIP GY: New pharmacological strategies for the treatment of heart failure. Curr. Opin. Investig. Drugs (2001) 2:923-928.
   PubMedGoogle Scholar
• YOUNG JB: New therapeutic choices in the management of acute congestive heart failure. Rev. Cardiovasc. Med. (2001) 2(Suppl. 2):S19-S24.
   Google Scholar
• DOGGRELL SA, BROWN L: Present and future pharmacotherapy for heart failure. Expert Opin. Pharmacother. (2002) 3(7):915-930.
   PubMedGoogle Scholar
• JESSUP M, BROZENA S: Heart failure. N. Engl. J. Med. (2003) 348:2007-2018.
   PubMed Web of Science ®Google Scholar
• KLAPHOLZ M, MAURER M, LOWE AM et al.: Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J. Am. Coll. Cardiol. (2004) 43:1432-1438.
   PubMed Web of Science ®Google Scholar
• REDFIELD MM, JACOBSEN SJ, BURNETT JC Jr et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 289:194-202.
   PubMed Web of Science ®Google Scholar
• MASIP J, BETBESE AJ, PAEZ J et al.: Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema: a randomised trial. Lancet (2000) 356(9248):2126-2132.
   PubMed Web of Science ®Google Scholar
• FARAH AE, ALOUSI AA, SCHWARZ RP Jr: Positive inotropic agents. Ann. Rev. Pharmacol. Toxicol. (1984) 24:275-328.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. (1991) 325:1468-1475.
   PubMed Web of Science ®Google Scholar
• ENDOH M, HORI M: Basic pharmacology and clinical application of new positive inotropic agents. Drugs Today (1993) 29:29-56.
   Google Scholar
• PACKER M, CATS AJ, FOWLER MB et al.: Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1658.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341:709-717.
   PubMed Web of Science ®Google Scholar
• SMITH ES III, TRUSSELL S, MENCER LJ: Prevention of heart failure. Curr. Opin. Cardiol. (2002) 17:512-517.
   PubMed Web of Science ®Google Scholar
• LEIER CV, BINKLEY PF: Parenteral inotropic support for advanced congestive heart failure. Prog. Cardiovasc. Dis. (1998) 41:207-224.
   PubMed Web of Science ®Google Scholar
• HATZIZACHARIAS A, MAKRIS T, KRESPI P et al.: Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am. Heart. J. (1999) 138(2 Pt 1):191-192.
   PubMedGoogle Scholar
• ENDOH M: The effects of various drugs on the myocardial inotropic response. Gen. Pharmacol. (1995) 26:1-31.
   PubMedGoogle Scholar
• ENDOH M: Changes in intracellular Ca2+ mobilization and Ca2+ sensitization as mechanisms of action of physiological interventions and inotropic agents in intact myocardial cells. Jpn Heart. J. (1998) 39:1-44.
   PubMedGoogle Scholar
• ENDOH M: Regulation of myocardial contractility by a downstream mechanism. Circ. Res. (1998) 83:230-232.
   PubMed Web of Science ®Google Scholar
• LEE JA, ALLEN DG: Calcium sensitisers: mechanisms of action and potential usefulness as inotropes. Cardiovasc. Res. (1997) 36:10-20.
   PubMed Web of Science ®Google Scholar
• NAGURO I, NAGAO T, ADACHI-AKAHANE S: Ser1901 of α1C subunit is required for the PKA-mediated enhancement of L-type Ca2+ channel currents but not for the negative shift of activation. FEBS Lett. (2001) 489:87-91.
   PubMed Web of Science ®Google Scholar
• HAGEMANN D, KUSCHEL M, KURAMOCHI T et al.: Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes. J. Biol. Chem. (2000) 275:22532-22536.
   PubMedGoogle Scholar
• GRANZIER HL, LABEIT S: The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ. Res. (2004) 94:284-295.
   PubMed Web of Science ®Google Scholar
• WESTFALL MV, TURNER I, ALBAYYA FP et al.: Troponin I chimera analysis of the cardiac myofilament tension response to protein kinase A. Am. J. Physiol. (2001) 280:C324-C332.
   Google Scholar
• FLASHMAN E, REDWOOD C, MOOLMAN-SMOOK J, WATKINS H: Cardiac myosin binding protein C: its role in physiology and disease. Circ. Res. (2004) 94:1279-1289.
   PubMed Web of Science ®Google Scholar
• SONG LS, WANG SQ, XIAO RP et al.: β-Adrenergic stimulation synchronizes intracellular Ca2+ release during excitation-contraction coupling in cardiac myocytes. Circ. Res. (2001) 88:794-801.
   PubMed Web of Science ®Google Scholar
• ENDOH M: Force–frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur. J. Pharmacol. (2004) 500:73-86.
   PubMedGoogle Scholar
• ENDOH M: The therapeutic potential of novel cardiotonic agents. Expert Opin. Invest. Drugs (2003) 12(5):735-750.
   PubMedGoogle Scholar
• GOMEZ AM, VALDIVIA HH, CHENG H et al.: Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science (1997) 276:800-806.
   PubMed Web of Science ®Google Scholar
• SUGAWARA H, SAKURAI K, ATSUMI H et al.: Differential alteration of cardiotonic effects of EMD 57033 and β-adrenoceptor agonists in volume-overload rabbit ventricular myocytes. J. Card. Fail. (2000) 6:338-349.
   PubMed Web of Science ®Google Scholar
• KOHI M, NOROTA I, TAKANASHI M et al.: On the mechanism of action of the β-1 partial agonist denopamine in regulation of myocardial contractility: effects on myocardial alpha adrenoceptors and intracellular Ca++ transients. J. Pharmacol. Exp. Ther. (1993) 265:1292-1300.
   PubMed Web of Science ®Google Scholar
• HABUCHI Y, YAMAMOTO T, NISHIO M et al.: Modulation of L-type Ca current by denopamine, a nonparenteral partial β1 stimulant, in rabbit ventricular cells. Naunyn Schmiedebergs Arch. Pharmacol. (1996) 354:437-443.
   PubMed Web of Science ®Google Scholar
• ENDOH M: Mechanisms of novel cardiotonic agents developed to treat the failing heart syndrome. In: New Horizons for Failing Heart Syndrome. Sasayama S (Ed.), Springer, Tokyo, Japan (1996):187-208.
   Google Scholar
• KUROSAWA H, NARITA H, KABURAKI M et al.: Prolongation of the life span of cardiomyopathic hamster by the adrenergic β1-selective partial agonist denopamine. Jpn J. Pharmacol. (1996) 72:325-333.
   PubMedGoogle Scholar
• NISHIO R, MATSUMORI A, SHIOI T et al.: Denopamine, a β1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. J. Am. Coll. Cardiol. (1998) 32:808-815.
   PubMed Web of Science ®Google Scholar
• BLINKS JR, ENDOH M: Modification of myofibrillar responsiveness to Ca++ as an inotropic mechanism. Circulation (1986) 73:III85-III98.
   PubMedGoogle Scholar
• RECHTMAN MP, VAN DER ZYPP A, MAJEWSKI H: Amrinone reduces ischaemia-reperfusion injury in rat heart. Eur. J. Pharmacol. (2000) 402:255-262.
   PubMed Web of Science ®Google Scholar
• CHANANI NK, COWAN DB, TAKEUCHI K et al.: Differential effects of amrinone and milrinone upon myocardial inflammatory signaling. Circulation (2002) 106(12 Suppl. 1):1284-1289.
   Google Scholar
• HARADA K, IIJIMA T: Differential modulation by adenylate cyclase of Ca2+ and delayed K+ current in ventricular myocytes. Am. J. Physiol. (1994) 266:H1551-H1557.
   Google Scholar
• HIRASAWA A, AWAJI T, HOSONO M et al.: Effects of a new forskolin derivative, NKH477, on canine ventricular arrhythmia models. J. Cardiovasc. Pharmacol. (1993) 22:847-851.
   PubMedGoogle Scholar
• ISHIZUKA O, HOSONO M, NAKAMURA K: Profile of cardiovascular effects of NKH477, a novel forskolin derivative, assessed in isolated, blood-perfused dog heart preparations: comparison with isoproterenol. J. Cardiovasc. Pharmacol. (1992) 20:261-267.
   PubMed Web of Science ®Google Scholar
• PACKER M, FOWLER MB, ROECKER EB et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 106:2194-2196.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA T, BABA A, SUZUKI M et al.: Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am. J. Cardiol. (2000) 85:1495-1497; A7.
   PubMed Web of Science ®Google Scholar
• LOWES BD, SIMON MA, TSVETKOVA TO et al.: Inotropes in the β-blocker era. Clin. Cardiol. (2000) 23:III11-III16.
   Google Scholar
• SAWADA H, ENDOH M: Pharmacological characterization of effects of UK-1745, a novel cardiotonic agent with β-adrenoceptor-blocking action, in aequorin-loaded canine right ventricular muscle. J. Mol. Cell. Cardiol. (1999) 31:1047-1062.
   Google Scholar
• SAGAWA T, NISHIO M, SAGAWA K et al.: Activation of purified cardiac ryanodine receptors by dihydropyridine agonists. Am. J. Physiol. (2001) 280:H1201-H1207.
   Google Scholar
• HOBAI IA, O’ROURKE B: Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation (2001) 103:1577-1584.
   PubMed Web of Science ®Google Scholar
• MAIER LS, SCHWAN C, SCHILLINGER W et al.: Gingerol, isoproterenol and ouabain normalize impaired post-rest behavior but not force–frequency relation in failing human myocardium. Cardiovasc. Res. (2000) 45:913-924.
   PubMed Web of Science ®Google Scholar
• ENDOH M: Mechanism of action of Ca2+ sensitizers – update 2001. Cardiovasc. Drugs Ther. (2001) 15:397-403.
   Google Scholar
• SOLARO RJ, RARICK HM: Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ. Res. (1998) 83:471-480.
   PubMed Web of Science ®Google Scholar
• LI G, MARTIN AF, SOLARO RJ: Localization of regions of troponin I important in deactivation of cardiac myofilaments by acidic pH. J. Mol. Cell. Cardiol. (2001) 33:1309-1320.
   PubMed Web of Science ®Google Scholar
• WESTFALL MV, ALBAYYA FP, TURNER II, METZGER JM: Chimera analysis of troponin I domains that influence Ca2+-activated myofilament tension in adult cardiac myocytes. Circ. Res. (2000) 86:470-477.
   PubMed Web of Science ®Google Scholar
• LI MX, SPYRACOPOULOS L, BEIER N et al.: Interaction of cardiac troponin C with Ca2+ sensitizer EMD 57033 and cardiac troponin I inhibitory peptide. Biochemistry (2000) 39:8782-8790.
   PubMed Web of Science ®Google Scholar
• WANG X, LI MX, SPYRACOPOULOS L et al.: Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033. J. Biol. Chem. (2001) 276:25456-25466.
   Google Scholar
• LEVIJOKI J, POLLESELLO P, KAIVOLA J et al.: Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J. Mol. Cell. Cardiol. (2000) 32:479-491.
   PubMed Web of Science ®Google Scholar
• KURIHARA S, KOMUKAI K: Cross-bridge-dependent changes in the intracellular Ca2+ concentration in mammalian cardiac muscles. Jpn Heart J. (1996) 37:143-152.
   PubMedGoogle Scholar
• WATANABE A, TOMOIKE H, ENDOH M: Ca2+ sensitizer Org-30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium. Am. J. Physiol. (1996) 271:H1829-H1839.
   Google Scholar
• LEE JA, SHAH N, WHITE J et al.: A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium-sensitizing effect. Clin. Sci. (1993) 84:141-144.
   PubMed Web of Science ®Google Scholar
• TRINES SA, SMITS CA, VAN DER MOER J et al.: Calcium sensitizer EMD 57033, but not the β1-adrenoceptor agonist dobutamine, increases mechanical efficiency in stunned myocardium. J. Cardiovasc. Pharmacol. (2002) 39:61-72.
   Google Scholar
• TSUTSUI H, KINUGAWA S, IDE T et al.: Positive inotropic effects of calcium sensitizers on normal and failing cardiac myocytes. J. Cardiovasc. Pharmacol. (2001) 37:16-24.
   PubMed Web of Science ®Google Scholar
• SATA M, SUGIURA S, YAMASHITA H et al.: Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin. Eur. J. Pharmacol. (1995) 290:55-59.
   PubMed Web of Science ®Google Scholar
• ENDOH M: Mechanisms of action of novel cardiotonic agents. J. Cardiovasc. Pharmacol. (2002) 40:323-338.
   PubMed Web of Science ®Google Scholar
• MATSUMORI A, NUNOKAWA Y, SASAYAMA S: Pimobendan inhibits the activation of transcription factor NF-κB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase. Life Sci. (2000) 67:2513-2519.
   PubMed Web of Science ®Google Scholar
• OHTE N, CHENG CP, SUZUKI M et al.: The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J. Pharmacol. Exp. Ther. (1997) 282:23-31.
   PubMed Web of Science ®Google Scholar
• LUBSEN J, JUST H, HJALMARSSON AC et al.: Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart (1996) 76:223-231.
   PubMed Web of Science ®Google Scholar
• ISHIKI R, ISHIHARA T, IZAWA H et al.: Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J. Cardiovasc. Pharmacol. (2000) 35:897-905.
   PubMed Web of Science ®Google Scholar
• EPOCH Study (The Effect of Pimobendan on Chronic Heart Failure Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ. J. (2002) 66:149-157.
   PubMedGoogle Scholar
• MATHEW L, KATZ SD: Calcium sensitizing agents in heart failure. Drug Aging (1998) 12:191-204.
   PubMed Web of Science ®Google Scholar
• HAIKALA H, KAIVOLA J, NISSINEN E et al.: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J. Mol. Cell. Cardiol. (1995) 27:1859-1866.
   PubMed Web of Science ®Google Scholar
• EDES I, KISS E, KITADA Y et al.: Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ. Res. (1995) 77:107-113.
   PubMed Web of Science ®Google Scholar
• HAIKALA H, NISSINEN E, ETEMADZADEH E et al.: Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol. (1995) 25:794-801.
   PubMed Web of Science ®Google Scholar
• HAIKALA H, LEVIJOKI J, LINDEN IB: Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J. Mol. Cell. Cardiol. (1995) 27:2155-2165.
   PubMed Web of Science ®Google Scholar
• HASENFUSS G, PIESKE B, CASTELL M et al.: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation (1998) 98:2141-2147.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI R, ENDOH M: Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br. J. Pharmacol. (2005) 145:1143-1152.
   PubMed Web of Science ®Google Scholar
• SATO S, TALUKDER MA, SUGAWARA H et al.: Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J. Mol. Cell. Cardiol. (1998) 30:1115-1128.
   PubMed Web of Science ®Google Scholar
• KOPUSTINSKIENE DM, POLLESELLO P, SARIS NE: Levosimendan is a mitochondrial KATP channel opener. Eur. J. Pharmacol. (2001) 428:311-314.
   PubMed Web of Science ®Google Scholar
• DU TOIT EF, MULLER CA, MCCARTHY J et al.: Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J. Pharmacol. Exp. Ther. (1999) 290:505-514.
   PubMedGoogle Scholar
• SLAWSKY MT, COLUCCI WS, GOTTLIEB SS et al.: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 102:2222-2227.
   PubMed Web of Science ®Google Scholar
• KIVIKKO M, LEHTONEN L, COLUCCI WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation (2003) 107:81-86.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI R, TALUKDER MA, ENDOH M: Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur. J. Pharmacol. (2000) 400:103-112.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI R, TALUKDER MA, ENDOH M: Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J. Cardiovasc. Pharmacol. (2000) 36:118-125.
   PubMed Web of Science ®Google Scholar
• BRIXIUS K, REICKE S, SCHWINGER RH: Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium. Am. J. Physiol. (2002) 282:H131-H137.
   Web of Science ®Google Scholar
• FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360:196-202.
   PubMed Web of Science ®Google Scholar
• GOMES UC, CLELAND JG: Heart failure update. Eur. J. Heart Fail. (1999) 1:301-302.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, MCGOWAN J: Levosimendan: a new era for inodilator therapy for heart failure? Curr. Opin. Cardiol. (2002) 17:257-265.
   PubMedGoogle Scholar
• BRIXIUS K, MEHLHORN U, BLOCH W et al.: Different effect of the Ca2+ sensitizers EMD 57033 and CGP-48506 on cross-bridge cycling in human myocardium. J. Pharmacol. Exp. Ther. (2000) 295:1284-1290.
   PubMed Web of Science ®Google Scholar
• KAWABATA Y, ENDOH M: Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ. Res. (1993) 72:597-606.
   PubMed Web of Science ®Google Scholar
• STAMM C, FRIEHS I, COWAN DB et al.: Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. Circulation (2002) 106(12 Suppl. 1):1290-1298.
   Google Scholar
• ENDOH M, SUGAWARA H, MINESHIMA M: Pharmacology of SCH00013: a novel Ca2+ sensitizer. Cardiovasc. Drug Rev. (2001) 19:345-366.
   PubMedGoogle Scholar
• SUGAWARA H, ENDOH M: A novel cardiotonic agent SCH00013 acts as a Ca++ sensitizer with no chronotropic activity in mammalian cardiac muscle. J. Pharmacol. Exp. Ther. (1998) 287:214-222.
   PubMed Web of Science ®Google Scholar
• MALIK F, ELIAS KA, FINER JT et al.: Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. J. Card. Fail. (2005) 11:S97.
   Google Scholar
• SUGAWARA H, ENDOH M: (-)-Enantiomer EMD 57439 antagonizes the Ca2+ sensitizing effect of (+)-enantiomer EMD 57033 on diastolic function but not on systolic function in rabbit ventricular cardiomyocytes. Jpn J. Pharmacol. (1999) 80:55-65.
   PubMedGoogle Scholar
• ENDOH M, BLINKS JR: Actions of sympathomimetic amines on the Ca2+ transients and contractions of rabbit myocardium: reciprocal changes in myofibrillar responsiveness to Ca2+ mediated through α- and β-adrenoceptors. Circ. Res. (1988) 62:247-265.
   PubMed Web of Science ®Google Scholar
• ENDOH M, YANAGISAWA T, MORITA T et al.: Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043. J. Pharmacol. Exp. Ther. (1985) 234:267-273.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI R, ENDOH M: Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. J. Cardiovasc. Pharmacol. (2001) 37:209-218.
   PubMed Web of Science ®Google Scholar
• SADAYAPPAN S, GULICK J, OSINSKA H et al.: Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ. Res. (2005) 97:1156-1163.
   PubMedGoogle Scholar
• MORANO I: Tuning the human heart molecular motors by myosin light chains. J. Mol. Med. (1999) 77:544-555.
   PubMed Web of Science ®Google Scholar
• CHU L, TAKAHASHI R, NOROTA I et al.: Signal transduction and Ca2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium. Circ. Res. (2003) 92:1024-1032.
   PubMedGoogle Scholar
• LOEB HS, BREDAKIS J, GUNNER RM: Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation (1977) 55:375-378.
   PubMed Web of Science ®Google Scholar
• STONER JD III, BOLEN JL, HARRISON DC: Comparison of dobutamine and dopamine in treatment of severe heart failure. Br. Heart J. (1977) 39:536-539.
   PubMedGoogle Scholar
• LEIER CV, HEBAN PT, HUSS P et al.: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation (1978) 58:466-475.
   PubMed Web of Science ®Google Scholar
• LIANG CS, SHERMAN LG, DOHERTY JU et al.: Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation (1984) 69:113-119.
   PubMed Web of Science ®Google Scholar
• UNVERFERTH DV, MAGORIEN RD, LEWIS RP et al.: Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am. Heart J. (1980) 100:622-630.
   PubMed Web of Science ®Google Scholar
• ERLEMEIER HH, KUPPER W, BLEIFELD W: Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance. Cardiovasc. Drugs Ther. (1992) 6:391-398.
   PubMedGoogle Scholar
• ADAMOPOULOS S, PIEPOLI M, QIANG F et al.: Effects of pulsed β-stimulant therapy on β-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet (1995) 345:344-349.
   PubMedGoogle Scholar
• LEIER CV, HUSS P, LEWIS RP et al.: Drug-induced conditioning in congestive heart failure. Circulation (1982) 65:1382-1387.
   PubMedGoogle Scholar
• DIES F, KRELL M, WHITLOW P et al.: Intermittent dobutamine in ambulatory outpatients with chronic failure. Circulation (1986) 74(Suppl. II):II-38.
   Google Scholar
• MILLER LW: Outpatient dobutamine for refractory congestive heart failure: advantages, techniques, and results. J. Heart Lung Transplant. (1991) 10:482-487.
   PubMed Web of Science ®Google Scholar
• MILLER LW, MERKLE EJ, JENNISON SH: Outpatient use of dobutamine to support patients awaiting heart transplantation. J. Heart Lung Transplant. (1994) 13:S126-S129.
   Google Scholar
• MARIUS-NUNEZ AL, HEANEY L, FERNANDEZ RN et al.: Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am. Heart J. (1996) 132:805-808.
   PubMedGoogle Scholar
• OLIVA F, LATINI R, POLITI A et al.: Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am. Heart J. (1999) 138:247-253.
   PubMed Web of Science ®Google Scholar
• ELIS A, BENTAL T, KIMCHI O et al.: Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin. Pharmacol. Ther. (1998) 63:682-685.
   PubMedGoogle Scholar
• O’CONNOR CM, GATTIS WA, URETSKY BF et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. (1999) 138:78-86.
   PubMed Web of Science ®Google Scholar
• SATOH Y, TANIGUCHI K, KOIKE A et al.: Short-term effects of denopamine on anaerobic threshold and related parameters in patients with chronic heart failure: a double-blind crossover study. Clin. Pharmacol. Ther. (1993) 53:562-569.
   PubMedGoogle Scholar
• LAMBERTZ H, MEYER J, ERBEL R: Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation (1984) 69:298-305.
   PubMed Web of Science ®Google Scholar
• PLUMMER AL: The development of drug tolerance to β2 adrenergic agents. Chest (1978) 73:949-957.
   PubMed Web of Science ®Google Scholar
• ROUSSEAU MF, POULEUR H, VINCENT MF: Effects of a cardioselective β1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am. J. Cardiol. (1983) 51:1267-1274.
   PubMedGoogle Scholar
• POULEUR H, ROUSSEAU MF, MENGEOT P et al.: Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new β1 adrenoceptor partial agonist, ICI 118,587. Eur. Heart J. (1982) 3(Suppl. D):123-127.
   PubMedGoogle Scholar
• MOLAJO AO, BENNETT DH: Effect of xamoterol (ICI 118587), a new β1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br. Heart J. (1985) 54:17-21.
   PubMedGoogle Scholar
• Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. Lancet (1988) 1:489-493.
   PubMed Web of Science ®Google Scholar
• MCALPINE HM, HENDERSON F, DARGIE H: Addition of xamoterol to captopril in severe chronic heart failure. Eur. J. Clin. Pharmacol. (1989) 36:A71.
   PubMedGoogle Scholar
• POULEUR H, HANET C, ROUSSEAU MF: The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors. Br. J. Clin. Pharmacol. (1989) 28(Suppl. 1):82S-83S.
   Google Scholar
• Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet (1990) 336:1-6.
   PubMed Web of Science ®Google Scholar
• BENOTTI JR, GROSSMAN W, BRAUNWALD E et al.: Hemodynamic assessment of amrinone. A new inotropic agent. N. Engl. J. Med. (1978) 299:1373-1377.
   PubMed Web of Science ®Google Scholar
• LEJEMTEL TH, KEUNG E, SONNENBLICK EH et al.: Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation (1979) 59:1098-1104.
   PubMed Web of Science ®Google Scholar
• MASSIE B, BOURASSA M, DIBIANCO R et al.: Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation (1985) 71:963-971.
   PubMed Web of Science ®Google Scholar
• FELKER GM, BENZA RL, CHANDLER AB et al.: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol. (2003) 41:997-1003.
   PubMed Web of Science ®Google Scholar
• ANDERSON JL: Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am. Heart J. (1991) 121:1956-1964.
   PubMed Web of Science ®Google Scholar
• SEINO Y, MOMOMURA S, TAKANO T et al.: Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Crit. Care Med. (1996) 24:1490-1497.
   PubMedGoogle Scholar
• CUFFE MS, CALIFF RM, ADAMS KF Jr et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 287:1541-1547.
   PubMed Web of Science ®Google Scholar
• BIDDLE TL, BENOTTI JR, CREAGER MA et al.: Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am. J. Cardiol. (1987) 59:1345-1350.
   PubMedGoogle Scholar
• EICHHORN EJ, KONSTAM MA, WEILAND DS et al.: Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1987) 60:1329-1333.
   PubMedGoogle Scholar
• KIMATA S, HIROSAWA K, KASANUKI H et al.: [A placebo- controlled, randomized, double-blind study of intravenous E-1020 (olprinone hydrochloride) infusion in patients with acute heart failure]. Rinsho and Kenkyu (1993) 70:903-916.
   Google Scholar
• A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group. Cardiovasc. Drugs Ther. (1990) 4:419-425.
   PubMedGoogle Scholar
• FELDMAN AM, BAUGHMAN KL, LEE WK et al.: Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1991) 68:1203-1210.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, BRISTOW MR, PARMLEY WW et al.: Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N. Engl. J. Med. (1993) 329:149-155.
   PubMed Web of Science ®Google Scholar
• COHN JN, GOLDSTEIN SO, GREENBERG BH et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med. (1998) 339:1810-1816.
   PubMed Web of Science ®Google Scholar
• SCHERRER-CROSBIE M, COCCA-SPOFFORD D, DISALVO TG et al.: Effect of vesnarinone on cardiac function in patients with severe congestive heart failure. Am. Heart J. (1998) 136:769-777.
   PubMedGoogle Scholar
• SORAN O, YOUNG JD, HOLUBKOV R et al.: Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group. J. Card. Fail. (1999) 5:195-200.
   PubMedGoogle Scholar
• NARAHARA KA: Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Am. Heart J. (1991) 121:1471-1479.
   PubMedGoogle Scholar
• BALIGADOO SJ, SUBRATTY H, MANRAZ M et al.: Effects of enoximone on quality of life. Int. J. Cardiol. (1990) 28(Suppl. 1):S29-S32.
   Google Scholar
• URETSKY BF, JESSUP M, KONSTAM MA et al.: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation (1990) 82:774-780.
   PubMed Web of Science ®Google Scholar
• LOWES BD, HIGGINBOTHAM M, PETROVICH L et al.: Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J. Am. Coll. Cardiol. (2000) 36:501-508.
   PubMed Web of Science ®Google Scholar
• SHAKAR SF, ABRAHAM WT, GILBERT EM et al.: Combined oral positive inotropic and β-blocker therapy for treatment of refractory class IV heart failure. J. Am. Coll. Cardiol. (1998) 31:1336-1340.
   PubMed Web of Science ®Google Scholar
• LOWES BD, SHAKAR SF, METRA M et al.: Rationale and design of the enoximone clinical trials program. J. Card. Fail. (2005) 11:659-669.
   PubMed Web of Science ®Google Scholar
• MORI M, TAKEUCHI M, TAKAOKA H et al.: Effect of NKH477, a new water-soluble forskolin derivative, on arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction: comparison with dobutamine. J. Cardiovasc. Pharmacol. (1994) 24:310-316.
   PubMedGoogle Scholar
• VAN MEEL JC, ENTZEROTH M, REDEMANN N et al.: Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate. Arzneimittelforschung (1995) 45:136-141.
   PubMedGoogle Scholar
• KATZ SD, KUBO SH, JESSUP M et al.: A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am. Heart J. (1992) 123:95-103.
   PubMed Web of Science ®Google Scholar
• KUBO SH, GOLLUB S, BOURGE R et al.: Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation (1992) 85:942-949.
   PubMed Web of Science ®Google Scholar
• REMME WJ, KRAYENBUHL HP, BAUMANN G et al.: Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Eur. Heart J. (1994) 15:947-956.
   PubMedGoogle Scholar
• NIEMINEN MS, AKKILA J, HASENFUSS G et al.: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. (2000) 36:1903-1912.
   PubMed Web of Science ®Google Scholar
• LUOTOLAHTI M, LAMMINTAUSTA O, UKKONEN H et al.: Levosimendan, a calcium sensitizer and potassium channel opener, is safe and improves left ventricular function in acute myocardial infarction. Circulation (1998) 98(Suppl. I):(I)105-(I)106.
   Google Scholar
• MOISEYEV VS, PODER P, ANDREJEVS N et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J. (2002) 23:1422-1432.
   PubMed Web of Science ®Google Scholar
• PACKER M: REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. American Heart Association Annual Meeting. Dallas, TX, USA (13 – 16 November 2005).
   Google Scholar
• MEBAZAA A: The SURVIVE-W trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. American Heart Association Annual Meeting. Dallas, TX, USA (13 – 16 November 2005).
   Google Scholar
• THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med (1997) 336:525-533.
   PubMed Web of Science ®Google Scholar
• ARTEAGA GM, KOBAYASHI T, SOLARO JR: Molecular actions of drugs that sensitize cardiac myofilaments to Ca2+. Ann. Med. (2002) 34:248-258.
   PubMed Web of Science ®Google Scholar
• KASS DA, SOLARO RJ: Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation (2006) 113:305-315.
   PubMed Web of Science ®Google Scholar